Hydrogen Therapy Helps Arthritis Patient Recover from Drug Side Effects
Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation
Research hubs: Rheumatoid Arthritis · Immune System · Musculoskeletal System
- Evidence type
- Case report or series · Human study
- Authors
- Ting-Hao Tu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2025
- PMID
- 40579028
- Study Type
- Human
- Participants
- 1
- Delivery
- Gas (Sustained Release)
- Outcome
- Positive
- Peer Reviewed
- Yes
- Cited by
- 1 (OpenAlex, as of November 2026)
- Country
- Taiwan
TL;DR
Molecular hydrogen therapy helped a patient with rheumatoid arthritis recover from serious side effects caused by a common medication.
Key Finding
A patient with severe methotrexate-induced side effects showed marked clinical improvement and normalized laboratory values after receiving molecular hydrogen therapy, with immune cell changes suggesting potential immune modulation.
Summary
This case report describes a 66-year-old woman with rheumatoid arthritis who developed severe side effects from methotrexate (a common RA medication), including low blood cell counts, mouth sores, and organ problems. When she was treated with molecular hydrogen therapy (hydrogen gas), her symptoms improved and her blood tests returned to normal. The study also found changes in immune cells that suggest hydrogen may help regulate the immune system while reducing methotrexate's harmful effects.
Practical Takeaway
While this single case report suggests hydrogen therapy may help reduce methotrexate's toxic effects in rheumatoid arthritis patients, it is too limited to draw firm conclusions—it describes only one person's experience. Much larger, controlled studies are needed before hydrogen can be recommended as a treatment for methotrexate side effects. Anyone taking methotrexate should discuss any new treatments with their doctor first.
Abstract (excerpt)
Background/aim: Rheumatoid arthritis (RA) is a chronic autoimmune disease with systemic manifestations. Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits; however, it is also associated with adverse effects, particularly myelosuppression. Molecular…